Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Orthofix Medical (OFIX) over the last 13 years, with Q3 2025 value amounting to $1.6 million.

  • Orthofix Medical's Amortization of Deferred Charges fell 204.33% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 10096.14%. This contributed to the annual value of $15.9 million for FY2024, which is 11206.99% up from last year.
  • Orthofix Medical's Amortization of Deferred Charges amounted to $1.6 million in Q3 2025, which was down 204.33% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Orthofix Medical's Amortization of Deferred Charges ranged from a high of $11.3 million in Q4 2024 and a low of $735000.0 during Q4 2022
  • Over the past 5 years, Orthofix Medical's median Amortization of Deferred Charges value was $1.2 million (recorded in 2023), while the average stood at $1.8 million.
  • In the last 5 years, Orthofix Medical's Amortization of Deferred Charges skyrocketed by 30707.48% in 2023 and then crashed by 2533.16% in 2025.
  • Over the past 5 years, Orthofix Medical's Amortization of Deferred Charges (Quarter) stood at $851000.0 in 2021, then decreased by 13.63% to $735000.0 in 2022, then soared by 307.07% to $3.0 million in 2023, then soared by 277.67% to $11.3 million in 2024, then plummeted by 86.0% to $1.6 million in 2025.
  • Its Amortization of Deferred Charges stands at $1.6 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.3 million for Q1 2025.